MedTrace Logo

Vitamin D and Omega-3 Inhibit Metabolic Syndrome

NCT01326442 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-06-13

No results posted yet for this study

Summary

The study will test the hypothesis that supplementing the diet of subjects with Metabolic Syndrome with 2000 IU vitamin D and 1.8 g omega-3 fatty acids (EPA + DHA) per day, will facilitate weight loss, improve body composition and reduce metabolic and biochemical risk factors associated with type II diabetes and cardiovascular disease. Adult men and women who meet the International Diabetes Federation criteria for Metabolic Syndrome will be enrolled and embark on a 16 week diet and exercise intervention using a low glycemic index diet with or without the supplementary vitamin D and omega-3. Subjects will be counseled weekly and blood collected at weeks 0 and 16.

Conditions

Interventions

OTHER

low glycemic diet

a low glycemic diet, calorie restricted with exercise sessions 3 times per week

DIETARY_SUPPLEMENT

vitamin D omega-3

2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.

Sponsors & Collaborators

  • University of Guelph

    lead OTHER

Principal Investigators

  • Kelly A Meckling, PhD · University of Guelph

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01326442 on ClinicalTrials.gov